Keros Therapeutics
KROS
163 hedge funds and large institutions have $2.03B invested in Keros Therapeutics in 2024 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 69 increasing their positions, 45 reducing their positions, and 15 closing their positions.
747% more call options, than puts
Call options by funds: $4.47M | Put options by funds: $528K
73% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 15
53% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 45
41% more capital invested
Capital invested by funds: $1.44B → $2.03B (+$591M)
7% more funds holding
Funds holding: 152 → 163 (+11)
5.82% more ownership
Funds ownership: 87.28% → 93.1% (+5.8%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.5M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$25.9M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.1M |
| 4 |
Alkeon Capital Management
New York
|
+$14.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$13.6M |
| 2 |
O
OrbiMed
New York
|
-$12.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.5M |
| 4 |
Goldman Sachs
New York
|
-$8.19M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$5.89M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
176
Innealta Capital
Austin,
Texas
| – | -$1K | -22 | Closed |
|
177
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$437 | -10 | Closed |
|
KROS Hedge Fund Activity: Q3 2024 in Review
163 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q3 2024, worth a combined $2.03B — up 41% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new KROS positions and 15 closed out — a net gain of 11 holders — while 69 added to existing stakes and 45 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $28.5M. The largest seller was Braidwell, cutting an estimated $13.6M.
- 163 institutional investors held Keros Therapeutics (KROS) as of Q3 2024, up from 152 in Q2 2024.
- Funds reported $2.03B of Keros Therapeutics stock for Q3 2024, up 41% quarter-over-quarter.
- 26 funds opened new Keros Therapeutics positions in Q3 2024 and 15 closed out, a net change of +11 holders.
- The largest Keros Therapeutics buyer in Q3 2024 was Point72 Asset Management, an estimated $28.5M added.
- The largest Keros Therapeutics seller in Q3 2024 was Braidwell, an estimated $13.6M sold.
Based on aggregated 13F filings for Q3 2024.